Testing HOPE treatment to prevent liver cancer return after transplant
Part of Cancer, Digestive system clinical trials.
This study tests a special way of preserving donated livers, called HOPE, to see if it lowers the chance of liver cancer coming back after a liver transplant. If you have liver cancer and are waiting for a transplant, this trial might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are listed for a liver transplant because of liver cancer (HCC)
- Your liver cancer diagnosis is confirmed by MRI, CT scan, or biopsy
- Your cancer is within certain size and number limits (the 'up-to-seven' criteria) or has been reduced to meet those limits with prior treatment
- You are able to give written consent to join the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to preserve donated livers with a machine called eXVIVO before transplant. It is for adults receiving their first liver transplant and aims to see if this preservation method improves outcomes.
This study looks at how well people do in the long run after liver transplant using donor livers that were preserved in a specific machine called DHOPE for more than 4 hours. It may help doctors understand whether this preservation method leads to better transplant outcomes over time.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This study collects information about how livers do after transplantation when they've been preserved using machine perfusion—a technique that keeps donor livers in better condition before surgery. Researchers want to understand which preservation methods work best to improve transplant success across Europe.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.